Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 07/27 07:06:42 am
83.36 CHF   -0.18%
07:21aNOVARTIS AG : Gets a Buy rating from Morgan Stanley
MD
02:03aArtios raises USD153m in Series C financing
DJ
07/23NOVARTIS AG : Buy rating from UBS
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : JP Morgan reiterates its Sell rating

06/04/2021 | 07:37am EDT

In a research note published by Richard Vosser, JP Morgan advises its customers to Sell the stock. The target price is unchanged and still at CHF 80.


ę MarketScreener with dpa-AFX Analyser 2021
All news about NOVARTIS AG
07:21aNOVARTIS AG : Gets a Buy rating from Morgan Stanley
MD
02:03aArtios raises USD153m in Series C financing
DJ
07/23NOVARTIS AG : Buy rating from UBS
MD
07/22GLOBAL MARKETS LIVE : AT&T, American Airlines, Biogen, Netflix, ABB...
07/22GLAXOSMITHKLINE : GSK appoints consumer head as CEO of new spin-off
RE
07/22NOVARTIS AG : Deutsche Bank is now Neutral
MD
07/22ANALYST RECOMMENDATIONS : Barclays, Chevron, Flutter, Netflix, Unilever...
07/22NOVARTIS AG : Credit Suisse sticks Neutral
MD
07/22NOVARTIS : ESG Update - July 22, 2021
PU
07/22NOVARTIS AG : Goldman Sachs remains its Buy rating
MD
More news
Financials (USD)
Sales 2021 51 962 M - -
Net income 2021 9 836 M - -
Net Debt 2021 23 006 M - -
P/E ratio 2021 20,2x
Yield 2021 3,59%
Capitalization 222 B 222 B -
EV / Sales 2021 4,72x
EV / Sales 2022 4,40x
Nbr of Employees 109 000
Free-Float 87,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 91,20 $
Average target price 105,25 $
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-0.17%221 954
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
ELI LILLY AND COMPANY44.05%221 084
ABBVIE INC.9.93%208 043